Cargando…

Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment

Rhabdomyosarcoma (RMS) is the most common type of pediatric soft tissue sarcoma. It is classified into two main subtypes: embryonal (eRMS) and alveolar (aRMS). MYC family proteins are frequently highly expressed in RMS tumors, with the highest levels correlated with poor prognosis. A pharmacological...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marchesi, Irene, Fais, Milena, Fiorentino, Francesco Paolo, Bordoni, Valentina, Sanna, Luca, Zoroddu, Stefano, Bagella, Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998669/ https://www.ncbi.nlm.nih.gov/pubmed/35408939 http://dx.doi.org/10.3390/ijms23073581

Ejemplares similares

PRC2: an epigenetic multiprotein complex with a key role in the development of rhabdomyosarcoma carcinogenesis
por: Zoroddu, Stefano, et al.
Publicado: (2021)

Silver Nanoparticles Derived by Artemisia arborescens Reveal Anticancer and Apoptosis-Inducing Effects
por: Bordoni, Valentina, et al.
Publicado: (2021)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

Design, synthesis, and biological screening of a series of 4′-fluoro-benzotriazole-acrylonitrile derivatives as microtubule-destabilising agents (MDAs)
por: Riu, Federico, et al.
Publicado: (2022)

Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes
por: Li, Feng, et al.
Publicado: (2020)

Bromodomain inhibitor JQ1 reversibly blocks IFN-γ production
por: Gibbons, Hunter R., et al.
Publicado: (2019)

MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells
por: Kato, Fuyumi, et al.
Publicado: (2016)

RNAseq Analysis of Novel 1,3,4-Oxadiazole Chalcogen Analogues Reveals Anti-Tubulin Properties on Cancer Cell Lines
por: Zoroddu, Stefano, et al.
Publicado: (2023)

The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
por: Zhao, Bei, et al.
Publicado: (2018)

Clarifying the molecular mechanism of tomentosin-induced antiproliferative and proapoptotic effects in human multiple myeloma via gene expression profile and genetic interaction network analysis
por: Virdis, Patrizia, et al.
Publicado: (2021)

Tomentosin a Sesquiterpene Lactone Induces Antiproliferative and Proapoptotic Effects in Human Burkitt Lymphoma by Deregulation of Anti- and Pro-Apoptotic Genes
por: Virdis, Patrizia, et al.
Publicado: (2021)

Enhancement of adenovirus infection and adenoviral vector-mediated gene delivery by bromodomain inhibitor JQ1
por: Lv, Baojie, et al.
Publicado: (2018)

Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer
por: Yamamoto, Keisuke, et al.
Publicado: (2016)

The bromodomain inhibitor JQ1+ reduces calcium-sensing receptor activity in pituitary cell lines
por: Lines, Kate E, et al.
Publicado: (2021)

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020)

Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells
por: Sui, Shiyao, et al.
Publicado: (2019)

BET bromodomain inhibitor JQ1 regulates spermatid development by changing chromatin conformation in mouse spermatogenesis
por: Wang, Xiaorong, et al.
Publicado: (2021)

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins by JQ1 Unravels a Novel Epigenetic Modulation to Control Lipid Homeostasis
por: Tonini, Claudia, et al.
Publicado: (2020)

The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo
por: Jostes, Sina, et al.
Publicado: (2016)

Bromodomain‐containing protein 4 inhibitor JQ1 promotes melanoma cell apoptosis by regulating mitochondrial dynamics
por: Li, Liyuan, et al.
Publicado: (2021)

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation
por: Li, Zichong, et al.
Publicado: (2013)

Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
por: Kumar, Krishan, et al.
Publicado: (2015)

The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors
por: Veneziani, Irene, et al.
Publicado: (2019)

Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1
por: Jung, Marie, et al.
Publicado: (2014)

BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1
por: Stewart, Helen Jayne Susan, et al.
Publicado: (2013)

Bromodomain and extra‐terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension
por: Mumby, Sharon, et al.
Publicado: (2016)

BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
por: Li, Ning, et al.
Publicado: (2018)

The Bromodomain Inhibitor JQ1 Enhances the Responses to All-trans Retinoic Acid in HL-60 and MV4-11 Leukemia Cells
por: Kang, Changhee, et al.
Publicado: (2018)

Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis
por: Zhang, Meng-Yi, et al.
Publicado: (2020)

The bromodomain inhibitor JQ1 up-regulates the long non-coding RNA MALAT1 in cultured human hepatic carcinoma cells
por: Choi, Hae In, et al.
Publicado: (2022)

Instant jqGrid
por: Manricks, Gabriel
Publicado: (2013)

The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer’s Disease
por: Magistri, Marco, et al.
Publicado: (2016)

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition
por: Yao, Weilong, et al.
Publicado: (2015)

Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts
por: Bian, Benjamin, et al.
Publicado: (2017)

Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway
por: Wen, Naiyan, et al.
Publicado: (2019)

Modulation of Virulence-Associated Traits in Aspergillus fumigatus by BET Inhibitor JQ1
por: Orekhova, Anastasia, et al.
Publicado: (2022)

Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells
por: Bauer, Karin, et al.
Publicado: (2018)

NMR Molecular Replacement Provides New Insights into Binding Modes to Bromodomains of BRD4 and TRIM24
por: Torres, Felix, et al.
Publicado: (2022)

Clinical Insight on Proton Therapy for Paediatric Rhabdomyosarcoma
por: Vennarini, Sabina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rgk38hdj9sm6b08hs9gdub4ff9